Biolinerx Ltd., of Tel Aviv, Israel, said it priced a public offering of about 29.4 million American depositary shares (ADSs), each representing one of its ordinary shares, at a price of 85 cents per ADS for gross proceeds of $25 million. Read More

Clearside Biomedical Inc., of Alpharetta, Ga., entered a strategic collaboration with Eyekor Inc., of Madison, Wisc., to support Clearside’s ophthalmic clinical trial activities. Read More

Argenx NV, of Breda, the Netherlands, said it dosed the first patient in a phase II study of ARGX-113 in primary immune thrombocytopenia (ITP). Read More

One of the challenges of developing a dengue virus vaccine is that there are four different variants of the virus, and antibodies that kill one subtype can actually exacerbate infection with another subtype. The process is known as antibody-dependent enhancement (ADE). Read More

With oncolytic virus therapeutics continuing to demonstrate their clinical potential in immuno-oncology, they have become hot commodities with companies looking to gain a foothold in the space. Read More

HONG KONG – A deal between South Korean biopharmaceutical firm Alteogen Inc. and Chinese company Qilu Pharmaceutical Co. Ltd. to complete development of a biosimilar drug suggests the technology gap between the two countries is closing, and underlines the fact that recent political tensions between the two countries have had little impact on the biotech industry. Read More

An Australian Senate committee recommended last week that Parliament pass the Therapeutic Goods Amendment Bill (2016 Measures No. 1) that would overhaul drug and device regulations to speed access to novel therapies and reduce regulatory red tape. Read More

SHANGHAI – Suzhou-based Innovent Biologics Inc. and Hanmi Pharmaceuticals Co. Ltd., of Seoul, South Korea, will pair up to co-develop and co-commercialize a bispecific immuno-oncology antibody for breast cancer with the possibility of other indications to follow. The molecule is expected to enter clinical trials in 2019. Read More

As Johnson & Johnson (J&J) tied the bow on its all-cash tender offer takeover of Actelion Ltd. to gain an impressive franchise in pulmonary arterial hypertension (PAH), an expected decision grew near on the device portion of United Therapeutics Corp.’s drug-device combo Remosynch – an implantable pump system for delivery of the PAH drug Remodulin (treprostinil). Read More

LONDON - The U.K./U.S. public-private partnership set up to rejuvenate early stage antibiotic research has awarded $24 million to 11 biotechs in its first round of grants. Read More